Recent Finacing
Recent Raise
Affimed is a Heidelberg-based clinical-stage biopharmaceutical company developing TandAb tetravalent bispecific antibodies that engage NK and T cells to target Hodgkin’s and non‑Hodgkin’s lymphoma.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
